IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer
Sydney, Australia 6 June 2022 Highlights IND approval received for SAR-Bombesin product, enabling a Phase II “SABRE” imaging trial to detect prostate cancer in up to 50 PSMA-negative participants in the US Approximately 20% of prostate cancer patients with biochemical recurrence are PSMA-PET negative and therefore unsuitable for the currently approved PSMA targeting agents, presenting…